Baratella Elisa, Ruaro Barbara, Marrocchio Cristina, Starvaggi Natalia, Salton Francesco, Giudici Fabiola, Quaia Emilio, Confalonieri Marco, Cova Maria Assunta
Department of Radiology, Cattinara Hospital, University of Trieste, Strada di Fiume 447, 34128 Trieste, Italy.
Department of Pneumology, Cattinara Hospital, Strada di Fiume 447, 34128 Trieste, Italy.
J Clin Med. 2021 Sep 2;10(17):3985. doi: 10.3390/jcm10173985.
The purpose of this study was to evaluate High-Resolution CT (HRCT) findings in SARS-CoV-2-related ARDS survivors treated with prolonged low-dose methylprednisolone after hospital discharge.
A total of 44 consecutive patients (M: 32, F: 12, average age: 64), hospitalised in our department from April to September 2020 for SARS-CoV-2-related ARDS, who had a postdischarge CT scan, were enrolled into this retrospective study. We reviewed the electronic medical charts to collect laboratory, clinical, and demographic data. The CT findings were evaluated and classified according to lung segmental distribution. The imaging findings were correlated with spirometry results and included ground glass opacities (GGOs), consolidations, reticulations, bronchiectasis/bronchiolectasis, linear bands, and loss of pulmonary volume.
Alterations in the pulmonary parenchyma were observed in 97.7% of patients at HRCT (median time lapse between ARDS diagnosis and HRCT: 2.8 months, range 0.9 to 6.7). The most common findings were linear bands (84%), followed by GGOs (75%), reticulations (34%), bronchiolectasis (32%), consolidations (30%), bronchiectasis (30%) and volume loss (25%). They had a symmetric distribution, and both lower lobes were the most affected areas.
A reticular pattern with a posterior distribution was observed 3 months after discharge from severe COVID-19 pneumonia, and this differs from previously described postCOVID-19 fibrotic-like changes. We hypothesized that the systematic use of prolonged low-dose of corticosteroid could be the main reason of this different CT scan appearance.
本研究旨在评估出院后接受长期小剂量甲基强的松龙治疗的新型冠状病毒肺炎相关急性呼吸窘迫综合征(SARS-CoV-2 相关 ARDS)幸存者的高分辨率 CT(HRCT)表现。
共有 44 例连续患者(男性 32 例,女性 12 例,平均年龄 64 岁)纳入本回顾性研究,这些患者于 2020 年 4 月至 9 月因 SARS-CoV-2 相关 ARDS 在我院住院,并进行了出院后 CT 扫描。我们查阅电子病历以收集实验室、临床和人口统计学数据。根据肺段分布对 CT 表现进行评估和分类。将影像学表现与肺功能测定结果相关联,包括磨玻璃影(GGO)、实变、网状影、支气管扩张/细支气管扩张、线状影和肺容积减小。
HRCT 检查发现 97.7%的患者存在肺实质改变(ARDS 诊断与 HRCT 之间的中位时间间隔:2.8 个月,范围 0.9 至 6.7 个月)。最常见的表现为线状影(84%),其次是磨玻璃影(75%)、网状影(34%)、细支气管扩张(32%)、实变(30%)、支气管扩张(30%)和肺容积减小(25%)。它们呈对称分布,双下肺是最常受累的区域。
在重症新型冠状病毒肺炎出院 3 个月后观察到一种以后部为主的网状模式,这与先前描述的新型冠状病毒肺炎后纤维化样改变不同。我们推测长期小剂量使用皮质类固醇可能是这种不同 CT 扫描表现的主要原因。